

46. OTC Vol. 160069.
47. Smith, G. H., "Diaper Rash and Prickly Heat Products," in *Handbook of Nonprescription Drugs*, 10th ed., American Pharmaceutical Association, Washington, DC, p. 546, 1993.
48. Wormser, H., "Poison Ivy and Poison Oak Products," in *Handbook of Nonprescription Drugs*, 10th ed., American Pharmaceutical Association, Washington, DC, p. 589-596, 1993.
49. *Physicians' Desk Reference for Nonprescription Drugs*, 15th ed., Medical Economics Data Production Co., Montvale, NJ, pp. 673 and 674, 1994.
50. Fabrizio, G., P. Morganti, and L. Cataldi, "Effecto Barriera Dell'Avena Colloidale in Dermatologia Pediatrica," *Chronica Dermatologica* 12:465-468, 1981.
51. Raab, W., "Allergologic and Clinical Trials with Aveeno Baby Cream," December 31, 1980, in Comment SUP1, Docket No. 78N-021P, Dockets Management Branch.
52. Fisher, A. A., "Pruritus Ani and Vulvae," in *Current Therapy—1982*, edited by H. F. Conn, W. B. Saunders Co., Philadelphia, PA, pp. 686-688, 1982.
53. Barkoff, J. R., "Pruritus Ani and Vulvae," in *Current Therapy—1973*, edited by H. F. Conn, W. B. Saunders Co., Philadelphia, PA, pp. 639-641, 1973.
54. Lewis, G. M. and C. E. Wheeler, Jr., *Practical Dermatology*, 3d ed., W. B. Saunders Co., Philadelphia, PA, p. 630, 1967.
55. Comment No. C77, Docket No. 78N-0301, Dockets Management Branch.
56. Letter from W. E. Gilbertson, FDA, to G. L. Carlson, S. C. Johnson & Son, Inc., coded LET 25, Docket No. 78N-0021, Dockets Management Branch.
57. Dick, L., "Colloidal Emollient Baths in Pediatric Dermatoses," *Archives of Pediatrics* 75:506-508, 1958.
58. Franks, A. G., "Dermatologic Uses of Baths," *American Practitioner and Digest of Treatment* 9:1998-1999, 1958.
59. Smith, G. C., "The Treatment of Various Dermatoses Associated With Dry Skin," *Journal of the South Carolina Medical Association* 54:282, 1958.
60. Memorandum of telephone conversation between G. L. Carlson, S. C. Johnson & Son, Inc., and T. North, FDA, dated June 20, 1994, in OTC Vol. 06DFM, Docket No. 78N-0021, Dockets Management Branch.
61. Summary Minutes of the Twenty-Third Meeting of the Advisory Review Panel on OTC Miscellaneous External Drug Products, January 29 and 30, 1978, included in OTC Vol. 06DFM, Docket No. 78N-0021, Dockets Management Branch.
62. "Bath Dermatologicals Emollient Preparations," in *Drug Facts and Comparisons*, Facts & Comparisons, Inc., St. Louis, MO, p. 613, 1992.
63. Labeling for Aveeno Bath and Aveeno Bath Oilated for Dry Skin, in OTC Vol. 06DFM, Docket No. 78N-0021, Dockets Management Branch.
64. Perry, H. O., "Treatment of Bullous Dermatoses" in *Pharmaceutical Therapeutics in Dermatology*, edited by M. Waisman, Charles C. Thomas, Springfield, IL, pp. 141-142, 1968.
65. Kligman, A. M., M. W. Greaves, and H. Steinman, "Water-induced Itching Without Cutaneous Signs," *Archives of Dermatology* 122:183-186, 1986.
66. Bartlett, B. H., "Atopic Dermatitis: Aetiology and Management," *Current Therapeutics*, 18:41-8, 1977.
67. Verbov, J., "Atopic Dermatitis," *The Practitioner* 223:820-825, 1979.
68. Transcript of the Twenty-Third Meeting of the Advisory Review Panel on OTC Miscellaneous External Drug Products, January 29, 1978, p. 98, in OTC Vol. 06DFM, Docket No. 78N-0021, Dockets Management Branch.
69. OTC Vol. 160167.
70. Letter from W. E. Gilbertson, FDA, to H. Dickstein, Warner-Lambert Co., coded LET27, Docket No. 78N-0021, Dockets Management Branch.
71. *The United States Pharmacopoeia 22—National Formulary 17*, United States Pharmacopoeial Convention, Inc., Rockville, MD, p. 1931, 1989.
72. OTC Vol. 160179.
73. Kligman, A. M. et al., "Some Aspects of Dry Skin and Its Treatment," in *Safety and Efficacy of Topical Drugs and Cosmetics*, edited by A. M. Kligman and J. J. Leyden, Grune & Stratton, Inc., New York, NY, pp. 221, 235, 1982.
74. *Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements*, 20th ed., Medical Economics Co., Inc., Montvale, NJ, p. 738, 1999.
75. *Handbook of Nonprescription Drugs*, 10th ed., American Pharmaceutical Association, Washington, pp. 840-853, 1993.
76. Letter from H. Jenkins, Summit Industries, Inc., to G. Rachanow, FDA, in OTC Vol. 06DFM, Docket No. 78N-0021, Dockets Management Branch.
77. Kaplan, J. Z., "Acceleration of Wound Healing by a Live Yeast Cell Derivative," study WM-185 dated April 5, 1983, submitted by Whitehall Laboratories, Comment No. C00034, vol. I, section I-A, Docket No. 78N-0021, Dockets Management Branch.
78. Kaplan, J. Z., "A Comparison of the Efficacy and Safety of Live Yeast Cell Derivative in Ointment Base (no Shark Liver Oil) vs. Ointment Base (no Live Yeast Cell Derivative and no Shark Liver Oil) As A Wound Healing Accelerator in Skin Graft Donor Sites," study WM-288, dated January 22, 1985, submitted by Whitehall Laboratories, Comment No. LET 12, vol. I, appendix 1 (medical summary) and vol. II (case report forms), Docket No. 78N-0021, Dockets Management Branch.
79. Comment No. SUP, Docket No. 78N-0021, Dockets Management Branch.
80. Kaplan, J. Z., "Acceleration of Wound Healing by a Live Yeast Cell Derivative," updated May 5, 1983, to include supporting raw data, submitted by Whitehall Laboratories, Comment No. AMD, Docket No. 78N-0021, Dockets Management Branch.
81. Statistical evaluations, reviews, and statements submitted by Whitehall Laboratories, Comment No. C00034, vol. I, sections I-B through I-F, Docket No. 78N-0021, Dockets Management Branch.
82. Comment No. C00057, Docket No. 78N-0021, Dockets Management Branch.
83. Comment No. LET 11, Docket No. 78N-0021, Dockets Management Branch.
84. Comment No. LET 12, vol. I, appendix 2 and appendix 3, Docket No. 78N-0021, Dockets Management Branch.
85. Comment No. LET 13, Docket No. 78N-0021, Dockets Management Branch.
86. Comment No. LET 14, Docket No. 78N-0021, Dockets Management Branch.
87. Comment No. C00034, vol. II, Docket No. 78N-0021, Dockets Management Branch.
88. Comment No. C00059, Docket No. 78N-0021, Dockets Management Branch.
89. Comment No. C00061, Docket No. 78N-0021, Dockets Management Branch.
90. Kaplan, J. Z., "Acceleration of Wound Healing by a Live Yeast Cell Derivative," *Archives of Surgery*, 119:1005-1008, 1984.
91. Letter from W. E. Gilbertson, FDA, to S. F. Barshay, Whitehall Laboratories, coded LET 10, Docket No. 78N-0021, Dockets Management Branch.
92. Letter from W. E. Gilbertson, FDA, to E. V. Henry, Whitehall Laboratories, coded LET 26, Docket No. 78N-0021, Dockets Management Branch.
93. Letter from W. E. Gilbertson, FDA, to E. V. Henry, Whitehall Laboratories, coded LET 15, Docket No. 78N-0021, Dockets Management Branch.
94. Letter from W. E. Gilbertson, FDA, to E. V. Henry, Whitehall Laboratories, coded LET 18, Docket No. 78N-0021, Dockets Management Branch.
95. Letter from W. E. Gilbertson, FDA, to J. R. Jacobs, Whitehall Laboratories, coded LET 21, Docket No. 78N-0021, Dockets Management Branch.
96. OTC Vol. 160060.
97. OTC Vol. 160052.
98. OTC Vol. 160086.
99. Oser, B. L. et al., "Toxicologic Studies of Petrolatum in Mice and Rats," *Toxicology and Applied Pharmacology* 7:382-401, 1965.
100. *Foods Chemicals Codex*, 3d ed., National Academy Press, Washington, DC, p. 221, 1981.
101. Lyght, E. E., ed., *The Merck Manual*, 9th ed., Merck & Co., Rahway, NJ, p. 1756, 1956.
102. Sollmann, T., *A Manual of Pharmacology*, 7th ed., W. B. Saunders Co., Philadelphia, PA, p. 122, 1948.
103. Schalek, A., *Fundamentals of Dermatology*, 2d ed., Lea & Febiger, Philadelphia, PA, p. 34, 1931.
104. Tobias, N., *Essentials of Dermatology*, 4th ed., J. B. Lippincott Co., Philadelphia, PA, p. 552, 1952.

List of Subjects

21 CFR Part 310

Administrative practice and procedure, Drugs, Labeling, Medical devices, Reporting and recordkeeping requirements.

21 CFR Parts 347 and 352

Labeling, Over-the-counter drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 310, 347, and 352 are amended as follows: